CA3097219A1 - Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid - Google Patents
Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid Download PDFInfo
- Publication number
- CA3097219A1 CA3097219A1 CA3097219A CA3097219A CA3097219A1 CA 3097219 A1 CA3097219 A1 CA 3097219A1 CA 3097219 A CA3097219 A CA 3097219A CA 3097219 A CA3097219 A CA 3097219A CA 3097219 A1 CA3097219 A1 CA 3097219A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- salt
- alkyl
- hydroxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862669135P | 2018-05-09 | 2018-05-09 | |
| US62/669,135 | 2018-05-09 | ||
| PCT/US2019/031310 WO2019217550A1 (en) | 2018-05-09 | 2019-05-08 | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3097219A1 true CA3097219A1 (en) | 2019-11-14 |
Family
ID=66625363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3097219A Pending CA3097219A1 (en) | 2018-05-09 | 2019-05-08 | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11713298B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3790863A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7440989B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20210006967A (cg-RX-API-DMAC10.html) |
| CN (1) | CN112088155A (cg-RX-API-DMAC10.html) |
| AR (1) | AR114886A1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2019265629B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3097219A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL278533B2 (cg-RX-API-DMAC10.html) |
| MX (2) | MX2020011845A (cg-RX-API-DMAC10.html) |
| TW (2) | TWI822776B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2019217550A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ623002A (en) | 2006-06-26 | 2015-08-28 | Akebia Therapeutics Inc | Prolyl hydroxylase inhibitors and methods of use |
| NO2686520T3 (cg-RX-API-DMAC10.html) | 2011-06-06 | 2018-03-17 | ||
| TWI665190B (zh) | 2013-11-15 | 2019-07-11 | 阿克比治療有限公司 | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途 |
| US11713298B2 (en) | 2018-05-09 | 2023-08-01 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| WO2020075199A1 (en) * | 2018-10-12 | 2020-04-16 | Mylan Laboratories Limited | Polymorphic forms of vadadustat |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| US12612367B2 (en) | 2019-12-10 | 2026-04-28 | Akebia Therapeutics, Inc. | Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative |
| CN112979541B (zh) * | 2019-12-17 | 2022-11-11 | 浙江大学 | 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用 |
| WO2021216530A1 (en) | 2020-04-20 | 2021-10-28 | Akebia Therapeutics, Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| CN111825606A (zh) * | 2020-06-17 | 2020-10-27 | 上海希迈医药科技有限公司 | 一种伐度司他晶型及其制备方法 |
| WO2022006427A1 (en) | 2020-07-02 | 2022-01-06 | Akebia Therapeutics, Inc. | Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat |
| GB202011431D0 (en) * | 2020-07-23 | 2020-09-09 | Johnson Matthey Plc | Polymorphs of vadadustat and methods for preparing the polymorphs |
| KR20240000649U (ko) | 2022-10-11 | 2024-04-18 | 성기봉 | 팥음료 |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3655679A (en) | 1969-06-25 | 1972-04-11 | Merck & Co Inc | Certain aryl pyridine carboxylic acid derivatives |
| US3703582A (en) | 1970-04-20 | 1972-11-21 | Merck & Co Inc | Aryl pyridine carboxylic acids in the treatment of inflammation |
| US3894920A (en) | 1971-12-21 | 1975-07-15 | Sagami Chem Res | Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives |
| US4016287A (en) | 1972-07-17 | 1977-04-05 | Boehringer Ingelheim Gmbh | Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof |
| TW219933B (cg-RX-API-DMAC10.html) | 1990-02-26 | 1994-02-01 | Lilly Co Eli | |
| US5405613A (en) | 1991-12-11 | 1995-04-11 | Creative Nutrition Canada Corp. | Vitamin/mineral composition |
| TW352384B (en) | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
| DE4219158A1 (de) | 1992-06-11 | 1993-12-16 | Thomae Gmbh Dr K | Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| ATE149485T1 (de) | 1993-11-02 | 1997-03-15 | Hoechst Ag | Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel |
| EP0650961B1 (de) | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| CA2138929A1 (en) | 1993-12-30 | 1995-07-01 | Klaus Weidmann | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
| DE4410480A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE4410423A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US5789426A (en) | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| JPH09221476A (ja) | 1995-12-15 | 1997-08-26 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
| EP0900202A1 (de) | 1996-04-30 | 1999-03-10 | Hoechst Aktiengesellschaft | 3-alkoxypyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| DE19650215A1 (de) | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| EP1024134A4 (en) | 1997-10-09 | 2003-05-14 | Ono Pharmaceutical Co | DERIVATIVES OF AMINOBUTANIC ACID |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| CA2325471C (en) | 1998-03-23 | 2010-08-17 | Aventis Pharmaceuticals Products Inc. | Piperididinyl and n-amidinopiperidinyl derivatives |
| US6159379A (en) | 1999-05-04 | 2000-12-12 | Baker Hughes Incorporated | Organic ammonium salts for the removal of water soluble organics in produced water |
| JP2001048786A (ja) | 1999-08-05 | 2001-02-20 | Yamanouchi Pharmaceut Co Ltd | 三環式ヘテロアリール誘導体 |
| US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
| US6849718B2 (en) | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
| US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| JP4590157B2 (ja) | 2001-03-21 | 2010-12-01 | アイシス イノヴェイション リミテッド | アッセイ、方法および手段 |
| SE0101327D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | New crystalline forms |
| US6566088B1 (en) | 2001-10-04 | 2003-05-20 | Board Of Regents, The University Of Texas System | Prolyl-4-hydroxylases |
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| HU229475B1 (en) | 2001-12-06 | 2014-01-28 | Fibrogen | Methods of increasing endogenous erythropoietin (epo) |
| EP1556033A4 (en) | 2002-05-17 | 2006-05-31 | Celgene Corp | METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES |
| IL166426A0 (en) | 2002-08-29 | 2006-01-15 | Merck & Co Inc | N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| EP1554394B1 (en) | 2002-10-16 | 2009-12-16 | Isis Innovation Limited | Screening methods using a structural model of FIH |
| EP1567528A1 (en) | 2002-11-21 | 2005-08-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| WO2005007192A2 (en) | 2003-06-06 | 2005-01-27 | Fibrogen, Inc. | Cytoprotection through the use of hif hydroxylase inhibitors |
| CN103145616B (zh) | 2003-06-06 | 2015-09-30 | 菲布罗根有限公司 | 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途 |
| GB0314129D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| WO2005108370A1 (ja) | 2004-04-16 | 2005-11-17 | Ajinomoto Co., Inc. | ベンゼン化合物 |
| AU2005250412B2 (en) | 2004-05-28 | 2009-09-17 | Fibrogen, Inc. | HIF prolyl hydroxylase activity assay |
| JP2008500951A (ja) | 2004-05-31 | 2008-01-17 | 田辺三菱製薬株式会社 | 二環化合物 |
| EA200700243A1 (ru) | 2004-07-14 | 2007-08-31 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы лечения гепатита с |
| TW200616969A (en) | 2004-09-17 | 2006-06-01 | Tanabe Seiyaku Co | Imidazole compound |
| US20080213404A1 (en) | 2005-02-04 | 2008-09-04 | Johnson Randall S | Hif Modulating Compounds and Methods of Use Thereof |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| CN101849943A (zh) | 2005-06-06 | 2010-10-06 | 菲布罗根公司 | 使用HIFα稳定剂的改进的贫血治疗 |
| AU2006259352A1 (en) | 2005-06-15 | 2006-12-28 | Fibrogen, Inc. | Use of HIF 1alfa modulators for treatment of cancer |
| US20070154482A1 (en) | 2005-09-12 | 2007-07-05 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| WO2007047194A2 (en) | 2005-10-11 | 2007-04-26 | Dana-Farber Cancer Institute, Inc. | Methods for treating mitf-related disorders |
| AU2006326662B2 (en) | 2005-12-09 | 2011-07-28 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof |
| US20090023666A1 (en) | 2006-01-09 | 2009-01-22 | BTG plc | Modulators of Hypoxia Inducible Factor-1 and Related Uses |
| WO2007082899A1 (en) | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
| JP4801451B2 (ja) | 2006-01-19 | 2011-10-26 | 株式会社日立ハイテクノロジーズ | 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法 |
| WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| ITMI20060179A1 (it) | 2006-02-02 | 2007-08-03 | Abiogen Pharma Spa | Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse |
| US7625927B2 (en) | 2006-02-27 | 2009-12-01 | Alcon Research, Ltd. | Method of treating glaucoma |
| US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| PE20071020A1 (es) | 2006-03-07 | 2007-12-11 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa |
| JP2009537558A (ja) | 2006-05-16 | 2009-10-29 | スミスクライン・ビーチャム・コーポレイション | プロリルヒドロキシラーゼ阻害剤 |
| TWI394747B (zh) | 2006-06-23 | 2013-05-01 | Smithkline Beecham Corp | 脯胺醯基羥化酶抑制劑 |
| NZ623002A (en) | 2006-06-26 | 2015-08-28 | Akebia Therapeutics Inc | Prolyl hydroxylase inhibitors and methods of use |
| TW200845994A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: prolyl hydroxylase inhibitors |
| CL2008000066A1 (es) | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
| ES2446418T3 (es) | 2007-04-18 | 2014-03-07 | Amgen, Inc | Derivados de indanona que inhiben la prolil hidroxilasa |
| WO2008130527A1 (en) | 2007-04-18 | 2008-10-30 | Merck & Co., Inc. | Novel 1,8-naphthyridine compounds |
| US8030346B2 (en) | 2007-05-04 | 2011-10-04 | Amgen Inc. | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity |
| EP2160187B1 (en) | 2007-05-16 | 2013-05-22 | Merck Sharp & Dohme Corp. | Spiroindalones |
| WO2008141731A2 (en) | 2007-05-18 | 2008-11-27 | Bayer Healthcare Ag | Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| CN101868251B (zh) | 2007-08-06 | 2012-10-10 | 千寿制药株式会社 | 含有HIF-1α和HIF-2α表达抑制物质的药物 |
| TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
| US20110028507A1 (en) | 2007-08-10 | 2011-02-03 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| WO2009035534A2 (en) | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009043093A1 (en) | 2007-10-04 | 2009-04-09 | Newsouth Innovations Pty Limited | Hif inhibition |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009067790A1 (en) | 2007-11-26 | 2009-06-04 | Uti Limited Partnership | STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION |
| JP2011505367A (ja) | 2007-11-30 | 2011-02-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| WO2009073497A2 (en) | 2007-11-30 | 2009-06-11 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
| EP2240178A4 (en) | 2007-12-19 | 2011-10-26 | Glaxosmithkline Llc | PROLYLHYDROXYLASEHEMMER |
| US20110003013A1 (en) | 2008-01-04 | 2011-01-06 | Garvan Institute Of Medical Research | Method of increasing metabolism |
| US8952160B2 (en) | 2008-01-11 | 2015-02-10 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity |
| SI2268618T1 (sl) | 2008-03-03 | 2015-09-30 | Novartis Ag | Spojine in sestavki kot modulatorji aktivnosti TLR |
| WO2009117676A2 (en) | 2008-03-20 | 2009-09-24 | Forest Laboratories Holdings Limited | Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase |
| AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
| MX2011000656A (es) | 2008-07-23 | 2011-02-23 | Hoffmann La Roche | Compuestos heterociclicos antiviricos. |
| BRPI0913485A2 (pt) | 2008-09-15 | 2016-06-07 | Kasina Laila Innova Pharmaceuticals Private Ltd | medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres. |
| WO2010056767A1 (en) | 2008-11-14 | 2010-05-20 | Fibrogen, Inc. | Thiochromene derivatives as hip hydroxylase inhibitors |
| WO2010128355A2 (en) * | 2008-12-26 | 2010-11-11 | Actavis Group Ptc Ehf | Improved processes for preparing substantially pure arformoterol and its intermediates |
| BRPI1013432B1 (pt) | 2009-03-31 | 2019-12-17 | Kissei Pharmaceutical | derivado de indolizina e composição farmacêutica |
| CA2774039A1 (en) | 2009-11-06 | 2011-05-12 | Aerpio Therapeutics Inc. | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha |
| CN103717214A (zh) | 2011-06-06 | 2014-04-09 | 阿克比治疗有限公司 | 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物 |
| NO2686520T3 (cg-RX-API-DMAC10.html) * | 2011-06-06 | 2018-03-17 | ||
| US20130022974A1 (en) | 2011-06-17 | 2013-01-24 | The Regents Of The University Of Michigan | Dna methylation profiles in cancer |
| CA2842730C (en) | 2011-07-22 | 2018-08-21 | Beijing Betta Pharmaceuticals Co., Ltd | Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| HUE066123T2 (hu) | 2013-06-13 | 2024-07-28 | Akebia Therapeutics Inc | Készítmények és módszerek anémia kezelésére |
| CA2921005A1 (en) | 2013-08-16 | 2015-02-19 | Ohio State Innovation Foundation | Compositions and methods for modulating dna methylation |
| TWI665190B (zh) | 2013-11-15 | 2019-07-11 | 阿克比治療有限公司 | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途 |
| RU2016133980A (ru) | 2014-01-23 | 2018-03-01 | Экебиа Терапьютикс, Инк. | Композиции и способы для лечения заболеваний глаз |
| MX2017008418A (es) * | 2014-12-30 | 2017-09-28 | Dow Agrosciences Llc | Picolinamidas con actividad fungicida. |
| CA2974691A1 (en) * | 2015-01-23 | 2016-07-28 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| AU2016235534A1 (en) | 2015-03-20 | 2017-10-12 | Akebia Therapeutics, Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
| CN106146491B (zh) * | 2015-03-27 | 2017-12-12 | 沈阳三生制药有限责任公司 | 被芳基或杂芳基取代的5‑羟基‑1,7‑萘啶化合物、其制备方法及其制药用途 |
| NZ735973A (en) | 2015-04-01 | 2023-06-30 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| CN105837502A (zh) * | 2016-04-05 | 2016-08-10 | 湖南欧亚生物有限公司 | 一种Vadadustat的合成方法 |
| US11713298B2 (en) | 2018-05-09 | 2023-08-01 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| CN111320577B (zh) | 2018-12-13 | 2023-06-23 | 广东东阳光药业有限公司 | 一种吡啶酰胺的制备方法及其应用 |
| PH12022551040A1 (en) | 2019-10-31 | 2023-05-29 | Akebia Therapeutics Inc | Therapeutic methods using vadadustat |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| AR121626A1 (es) | 2020-03-20 | 2022-06-22 | Akebia Therapeutics Inc | Compuestos inhibidores de phd, composiciones y métodos de uso |
| KR20220156890A (ko) | 2020-03-20 | 2022-11-28 | 아케비아 테라퓨틱스 인코포레이티드 | Phd 억제제 화합물, 조성물, 및 용도 |
| EP4121425A1 (en) | 2020-03-20 | 2023-01-25 | Akebia Therapeutics Inc. | Phd inhibitor compounds, compositions, and use |
-
2019
- 2019-05-08 US US17/053,614 patent/US11713298B2/en active Active
- 2019-05-08 TW TW108115898A patent/TWI822776B/zh active
- 2019-05-08 KR KR1020207035252A patent/KR20210006967A/ko not_active Ceased
- 2019-05-08 AR ARP190101226A patent/AR114886A1/es unknown
- 2019-05-08 WO PCT/US2019/031310 patent/WO2019217550A1/en not_active Ceased
- 2019-05-08 EP EP19725555.7A patent/EP3790863A1/en active Pending
- 2019-05-08 MX MX2020011845A patent/MX2020011845A/es unknown
- 2019-05-08 AU AU2019265629A patent/AU2019265629B2/en active Active
- 2019-05-08 CA CA3097219A patent/CA3097219A1/en active Pending
- 2019-05-08 TW TW112140875A patent/TWI926230B/zh active
- 2019-05-08 IL IL278533A patent/IL278533B2/en unknown
- 2019-05-08 JP JP2020562673A patent/JP7440989B2/ja active Active
- 2019-05-08 CN CN201980030849.4A patent/CN112088155A/zh active Pending
-
2020
- 2020-11-05 MX MX2024014558A patent/MX2024014558A/es unknown
-
2023
- 2023-06-13 US US18/334,101 patent/US12269802B2/en active Active
-
2024
- 2024-02-09 JP JP2024018279A patent/JP2024054276A/ja active Pending
-
2025
- 2025-03-05 US US19/071,033 patent/US20250243164A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020011845A (es) | 2021-01-15 |
| TWI926230B (zh) | 2026-05-21 |
| US11713298B2 (en) | 2023-08-01 |
| TWI822776B (zh) | 2023-11-21 |
| US12269802B2 (en) | 2025-04-08 |
| IL278533B1 (en) | 2025-10-01 |
| EP3790863A1 (en) | 2021-03-17 |
| JP2021523152A (ja) | 2021-09-02 |
| KR20210006967A (ko) | 2021-01-19 |
| TW202406895A (zh) | 2024-02-16 |
| WO2019217550A1 (en) | 2019-11-14 |
| IL278533A (cg-RX-API-DMAC10.html) | 2021-01-31 |
| AU2019265629B2 (en) | 2024-09-12 |
| AU2019265629A1 (en) | 2021-01-07 |
| US20240158354A1 (en) | 2024-05-16 |
| US20210070709A1 (en) | 2021-03-11 |
| CN112088155A (zh) | 2020-12-15 |
| MX2024014558A (es) | 2025-01-09 |
| JP7440989B2 (ja) | 2024-02-29 |
| US20250243164A1 (en) | 2025-07-31 |
| AR114886A1 (es) | 2020-10-28 |
| IL278533B2 (en) | 2026-02-01 |
| TW201946903A (zh) | 2019-12-16 |
| JP2024054276A (ja) | 2024-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12269802B2 (en) | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino] acetic acid | |
| JP7522799B2 (ja) | オメカムティブメカルビルの合成 | |
| ES2842749T3 (es) | Procesos para preparar inhibidores de ASK1 | |
| WO2020147861A1 (zh) | 一种β-三氟甲基酰胺类化合物的电化学制备方法 | |
| EA010633B1 (ru) | Новые бензальдоксимы, способ получения бензальдоксимов и его применение | |
| WO2022006427A1 (en) | Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat | |
| AU2020401539B2 (en) | Process and intermediate for the preparation of oxetan-2-ylmethanamine | |
| JP2019530691A (ja) | 新規なキラル配位子、金属キレート、数種類の非天然アミノ酸、マラビロクおよびその重要中間体の合成方法 | |
| KR102477924B1 (ko) | 인돌 카르복스아미드 화합물을 제조하는 방법 | |
| DK2401253T3 (en) | Method for producing etoricoxib | |
| RU2833026C2 (ru) | Способ получения 2-[[5-(3-хлорфенил)-3-гидроксипиридин-2-карбонил]амино]уксусной кислоты | |
| HU216444B (hu) | Eljárás fenil-ecetsav-származékok előállítására | |
| KR102919305B1 (ko) | 치환된 2-[2-(페닐)에틸아미노]알칸아미드 유도체를 제조하는 방법 | |
| CN103613513B (zh) | 盐酸米那普仑中间体及其制备方法和应用 | |
| CN113816955B (zh) | 一种ret激酶抑制剂中间体及其制备方法 | |
| DK2655321T3 (en) | PURIFICATION OF STARTING MATERIAL BY CRYSTALLIZATION | |
| Zhang et al. | Synthesis of an impurity in crude roflumilast | |
| JP6084570B2 (ja) | 3,4−ジヒドロイソキノリン誘導体の製造方法 | |
| KR101144776B1 (ko) | 광학 활성 벤젠설폰아마이드 유도체의 제조방법 | |
| JP2026501856A (ja) | テトラヒドロ-1-ナフチルアミン及びその誘導体の調製方法 | |
| JP2007106722A5 (ja) | 18Fで標識したアミノ酸O-(2-[18F]fluoroethyl)-L-Tyrosineの前駆体の製造方法。 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240508 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250402 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250402 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250513 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250915 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251121 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251121 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260311 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260401 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260401 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260706 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260708 |